Omar Mahmoud Azzam
Research Subjects
Omar Mahmoud Azzam has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Ali Mohamed
Intensive Care Department, Theodor Bilharz Institute, Giza, Egypt
1 shared publication - Alaa Aly Mohamed Abouaggour
Mediclinic Hospital, Abu Dhabi, United Arab Emirates
1 shared publication - Amal Ahmed Mohamed
Biochemistry Department, National Hepatology and Tropical Medicine Research Institute, The General Organization for Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
1 shared publication - Amira Yones Mohamed
Department of Internal Medicine, Matarya Teaching Hospital, Cairo, Egypt
1 shared publication - Eman AlHussain A. Gawad
Clinical Pathology Department, Clinical and Chemical Pathology, Cairo University, Cairo 11796, Egypt
1 shared publication - Gamil M. Abdallah
Biochemistry department, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 December 2024
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 9 (4) , 1249-1256
Evaluation of miRNA-146a, miRNA-34a, and pro-inflammatory cytokines as a potential early indicators for type 1 diabetes mellitus
Type I diabetes mellitus (T1DM) is one of the most common chronic autoimmune diseases worldwide. miRNAs are a class of small non-coding RNA molecules that have been linked to immune system functions, β-cell metabolism, proliferation, and death, all of which contribute to pathogenesis of TIDM. Dysregulated miRNAs have been identified in Egyptian TIDM patients. Several miRNAs were profiled in Egyptian TIDM patients to determine whether they can be used as molecular biomarkers for T1DM. The relationship between the investigated miRNAs and pro-inflammatory cytokines (TNF-α and IL-6) has also been evaluated in the development of TIDM, in addition to the creation of a proposed model for TIDM prediction. Case-control study included 177 Egyptian patients with confirmed type I diabetes mellitus and 177 healthy individuals. MiRNA-34 and miRNA-146 were detected in serum samples using real-time PCR, whereas TNF-α and IL-6 levels were assessed using ELIZA. Patients with TIDM showed a significant decrease in the expression of miRNA-146, with a cut-off value ≤ 3.3, 48 % specificity, and 92.1 % sensitivity, whereas miRNA-34 had the highest sensitivity (95.5 %) and specificity (97.2 %) for differentiating diabetic patients from controls. Furthermore, other diagnostic proinflammatory markers showed lower sensitivity and specificity. Serum levels of miRNA-34a, miRNA-146, IL-6, and TNF-α provide new insights into T1DM pathogenesis and could be used for screening and diagnosis purposes. They can be also a potential therapeutic target, as well as allowing for more strategies to improve T1DM disease outcomes.
- 1 December 2024
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 9 (4) , 1249-1256
Open AccessEvaluation of miRNA-146a, miRNA-34a, and pro-inflammatory cytokines as a potential early indicators for type 1 diabetes mellitus
Type I diabetes mellitus (T1DM) is one of the most common chronic autoimmune diseases worldwide. miRNAs are a class of small non-coding RNA molecules that have been linked to immune system functions, β-cell metabolism, proliferation, and death, all of which contribute to pathogenesis of TIDM. Dysregulated miRNAs have been identified in Egyptian TIDM patients. Several miRNAs were profiled in Egyptian TIDM patients to determine whether they can be used as molecular biomarkers for T1DM. The relationship between the investigated miRNAs and pro-inflammatory cytokines (TNF-α and IL-6) has also been evaluated in the development of TIDM, in addition to the creation of a proposed model for TIDM prediction. Case-control study included 177 Egyptian patients with confirmed type I diabetes mellitus and 177 healthy individuals. MiRNA-34 and miRNA-146 were detected in serum samples using real-time PCR, whereas TNF-α and IL-6 levels were assessed using ELIZA. Patients with TIDM showed a significant decrease in the expression of miRNA-146, with a cut-off value ≤ 3.3, 48 % specificity, and 92.1 % sensitivity, whereas miRNA-34 had the highest sensitivity (95.5 %) and specificity (97.2 %) for differentiating diabetic patients from controls. Furthermore, other diagnostic proinflammatory markers showed lower sensitivity and specificity. Serum levels of miRNA-34a, miRNA-146, IL-6, and TNF-α provide new insights into T1DM pathogenesis and could be used for screening and diagnosis purposes. They can be also a potential therapeutic target, as well as allowing for more strategies to improve T1DM disease outcomes.
- Open Access
- 1 January 2024
- Published by General Organization For Teaching Hospitals and Institutes in Journal of Medicine in Scientific Research
- Vol. 8 (2) , 3
Study of Transient Elastography Changes and Biochemical Effects of Direct Acting Antiviral Regimens in Egyptian HCV Patients
Background: In 2014–2015, a new era in the clinical practice of managing chronic HCV using direct antiviral drugs (DAAs) began. The results of DAAS therapy are promising, with higher sustained virological response (SVR) rates, shorter, more efficient regimens, and less treatment-related side effects in HCV patients. For many years, the field of liver specialists has focused most of its study and debate on the retrogradation of liver fibrosis. Recent evidence, however, has shown that fibrosis decline occurs in a variety of chronic liver disorders, including persistent viral hepatitis. Objective: to assess the biochemical effects of various DAAS regimens and changes in transient elastography results in individuals with chronic liver disease caused by HCV. Methods: This research involved 100 Egyptian patients with chronic hepatitis C who were treated at the Ahmed Maher Teaching Hospital's Viral Hepatitis Unit. Results: Over the course of the study, there were statistically significant changes in the liver profile of the group under investigation. Significant progress is shown following SVR1 and SVR2. Additionally, there is a discernible improvement in the tested population's grade of fibrosis as determined by TE measurements. After three months (SVR1), 2% of patients and twelve percent of patients after six months (SVR2), respectively, showed a significant regression from F4 to F3. Before therapy, the proportion of patients with F0 (no fibrosis) was 4%; after three months (SVR1) and six months (SVR2), it was 14% and 18%, respectively. Improvements in the FIB-4 score were highly statistically significant during the trial's duration. Patients with F4 grade fibrosis saw significant improvements in their scores; after SVR1 and SVR2, respectively, their percentage dropped from 56% prior to treatment to 42% and 38%. Fib-4 had a sensitivity of 50%, specificity of 92.9%, PPV of 94.7%, NPV of 41.9%, and accuracy of 62% when it came to predicting TE measurements. When predicting TE readings, the APRI score's sensitivity was 86.1%, specificity was 64.3%, PPV was 86.1%, NPV was 64.3%, and accuracy was 80%. When it came to predicting liver fibrosis, TE measurements showed a 72% sensitivity and a 38% sensitivity for FIB-4. The sensitivity rate increased to 74% when liver fibrosis was predicted using the FIB-4 score in addition to TE measurements. The percentage of sensitivity rose to 82% when we used the APRI score and TE measurements. Conclusion: For many years, the field of liver specialists has focused most of its study and debate on the retrogradation of liver fibrosis. Transient elastography and other non-invasive fibrosis scores like FIB-4 and APRI show significant improvements in hepatic fibrosis measurements after DAAS-based treatment. Improvements in liver functions were linked to improvements in fibrosis scores, suggesting a notable reduction in the necro-inflammatory response.
- 1 January 2024
- Published by General Organization For Teaching Hospitals and Institutes in Journal of Medicine in Scientific Research
- Vol. 8 (2) , 3
Open AccessStudy of Transient Elastography Changes and Biochemical Effects of Direct Acting Antiviral Regimens in Egyptian HCV Patients
Background: In 2014–2015, a new era in the clinical practice of managing chronic HCV using direct antiviral drugs (DAAs) began. The results of DAAS therapy are promising, with higher sustained virological response (SVR) rates, shorter, more efficient regimens, and less treatment-related side effects in HCV patients. For many years, the field of liver specialists has focused most of its study and debate on the retrogradation of liver fibrosis. Recent evidence, however, has shown that fibrosis decline occurs in a variety of chronic liver disorders, including persistent viral hepatitis. Objective: to assess the biochemical effects of various DAAS regimens and changes in transient elastography results in individuals with chronic liver disease caused by HCV. Methods: This research involved 100 Egyptian patients with chronic hepatitis C who were treated at the Ahmed Maher Teaching Hospital's Viral Hepatitis Unit. Results: Over the course of the study, there were statistically significant changes in the liver profile of the group under investigation. Significant progress is shown following SVR1 and SVR2. Additionally, there is a discernible improvement in the tested population's grade of fibrosis as determined by TE measurements. After three months (SVR1), 2% of patients and twelve percent of patients after six months (SVR2), respectively, showed a significant regression from F4 to F3. Before therapy, the proportion of patients with F0 (no fibrosis) was 4%; after three months (SVR1) and six months (SVR2), it was 14% and 18%, respectively. Improvements in the FIB-4 score were highly statistically significant during the trial's duration. Patients with F4 grade fibrosis saw significant improvements in their scores; after SVR1 and SVR2, respectively, their percentage dropped from 56% prior to treatment to 42% and 38%. Fib-4 had a sensitivity of 50%, specificity of 92.9%, PPV of 94.7%, NPV of 41.9%, and accuracy of 62% when it came to predicting TE measurements. When predicting TE readings, the APRI score's sensitivity was 86.1%, specificity was 64.3%, PPV was 86.1%, NPV was 64.3%, and accuracy was 80%. When it came to predicting liver fibrosis, TE measurements showed a 72% sensitivity and a 38% sensitivity for FIB-4. The sensitivity rate increased to 74% when liver fibrosis was predicted using the FIB-4 score in addition to TE measurements. The percentage of sensitivity rose to 82% when we used the APRI score and TE measurements. Conclusion: For many years, the field of liver specialists has focused most of its study and debate on the retrogradation of liver fibrosis. Transient elastography and other non-invasive fibrosis scores like FIB-4 and APRI show significant improvements in hepatic fibrosis measurements after DAAS-based treatment. Improvements in liver functions were linked to improvements in fibrosis scores, suggesting a notable reduction in the necro-inflammatory response.
- Open Access
- 1 January 2024
- Published by General Organization For Teaching Hospitals and Institutes in Journal of Medicine in Scientific Research
- Vol. 8 (1) , 12
Study of Association of Helicobacter pylori Infection with Portal Hypertensive Gastropathy (PHG) in Patients with Liver Cirrhosis
Background: Liver cirrhosis disease is regarded as a major global health concern and is linked to several insults. One of its most frequent injuries, portal hypertensive gastropathy (PHG), can cause bleeding in the gastrointestinal tract. With a global prevalence of 50%, Helicobacter pylori (H. pylori) is regarded as one of the most prevalent harmful organisms. As of right moment, it is unclear how H. pylori infection and PHG are related. Objective: To find out if PHG severity in cirrhotic cases is associated with H. pylori infection, and to explore the association between H. pylori infection and PHG. Methodology: In a retrospective research, individuals with upper endoscopy-diagnosed cirrhosis were divided into two groups based on whether PHG was present or absent. Group 1 consisted of 13 cirrhotic individuals who were age and sex matched and did not have PHG. Group 2 consisted of 47 cirrhotic patients with varying PHG grades who were age and sex matched. PHG and an H. pylori infection were found by endoscopic evaluation. Results: According to histology, 30 patients (about 50%) had H. pylori infection. Patients with PHG who were cirrhotic had a higher prevalence of H. pylori infection (86.7%) compared to those without PHG (13.3%) (P=0.038). Those with PHG had a higher prevalence of H. pylori infection than those without PHG (p-value = 0.038). Conclusion: The results of this study indicate that in cirrhosis patients, H. pylori infection and PHG are significantly correlated. Compared to patients without PHG, those with PHG experienced a significantly higher prevalence of H. pylori infection.
- 1 January 2024
- Published by General Organization For Teaching Hospitals and Institutes in Journal of Medicine in Scientific Research
- Vol. 8 (1) , 12
Open AccessStudy of Association of Helicobacter pylori Infection with Portal Hypertensive Gastropathy (PHG) in Patients with Liver Cirrhosis
Background: Liver cirrhosis disease is regarded as a major global health concern and is linked to several insults. One of its most frequent injuries, portal hypertensive gastropathy (PHG), can cause bleeding in the gastrointestinal tract. With a global prevalence of 50%, Helicobacter pylori (H. pylori) is regarded as one of the most prevalent harmful organisms. As of right moment, it is unclear how H. pylori infection and PHG are related. Objective: To find out if PHG severity in cirrhotic cases is associated with H. pylori infection, and to explore the association between H. pylori infection and PHG. Methodology: In a retrospective research, individuals with upper endoscopy-diagnosed cirrhosis were divided into two groups based on whether PHG was present or absent. Group 1 consisted of 13 cirrhotic individuals who were age and sex matched and did not have PHG. Group 2 consisted of 47 cirrhotic patients with varying PHG grades who were age and sex matched. PHG and an H. pylori infection were found by endoscopic evaluation. Results: According to histology, 30 patients (about 50%) had H. pylori infection. Patients with PHG who were cirrhotic had a higher prevalence of H. pylori infection (86.7%) compared to those without PHG (13.3%) (P=0.038). Those with PHG had a higher prevalence of H. pylori infection than those without PHG (p-value = 0.038). Conclusion: The results of this study indicate that in cirrhosis patients, H. pylori infection and PHG are significantly correlated. Compared to patients without PHG, those with PHG experienced a significantly higher prevalence of H. pylori infection.